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Summary 
Recognition of major histocompatibility complex class I molecules by natural killer (NK) cells 
leads to inhibition of target cell lysis. Based on the capacity of different human histocompatibil- 
ity leukocyte antigen (HLA)-C and HLA-B molecules to inhibit target cell lysis by NK lines 
and clones, three NK allospecificities have been defined: NK1 and NK2 cells are inhibited by 
different HLA-C allotypes and NK3 cells by some HLA-B allotypes. The NK1  and NK2 in- 
hibitory ligands  on target cells correspond to a dimorphism of HLA-C at residues 77 and 80 in 
the cxl helix: Asn77-Lys80 in NK1 and Ser77-Asn80 in NK2 inhibitory ligands.  It has been re- 
ported that protection from NK1  killers  depended on the presence of the Lys residue at posi- 
tion 80, an upward pointing residue near the end of the otl helix (and not on Asn77), whereas 
inhibition of NK2 effector cells required Ser77, a residue deep in the F pocket and interacting 
with the peptide (and not Asn80). As part of ongoing experiments to investigate the structural 
requirements for NK cell inhibition by HLA-C locus alleles,  we also examined the effects of 
mutations at residues 77 and 80 on the ability of HLA-C alleles to confer protection from NK 
lysis. We present data  confirming that the NK1  specificity depended on Lys80 (and not on 
Asn77);  however recognition of NK2 ligands  by NK cells was  also  controlled by the amino 
acid at position 80  (Asn),  and mutation of Ser77 had no effect. Furthermore, bound peptide 
was shown to be unnecessary for the inhibition of NK cell-mediated lysis since HLA-C mole- 
curs assembled in the absence ofpeptide in RMA-S cells at 26~  were fully competent to in- 
hibit NK cells specifically.  The implications of these data for peptide-independent recognition 
of HLA-C by NK receptors are discussed. 
O 
ne  recognized function of NK cells  is  in  mediating 
the  destruction of cells  that have lost expression of 
HLA class I molecules (1), for example, virus-infected cells 
that have downregulated surface class I expression by one 
of several possible mechanisms.  Recognition of HLA de- 
terminants by human NK cells is mediated by a family of 
inhibitory receptors (NKIR) 1 that are members  of the  Ig 
superfamily (2-4). Recognition of MHC  class I molecules 
by these receptors leads to the generation of a negative sig- 
nal in NK cells and thus inhibition of the lytic process (5, 
6).  To date, four NK cell specificities have been identified 
1Abbreviations used in  this paper: f32m, 132-microglobulin;  NKIP., natural 
killer inhibitory  receptors; TAP, transporter  associated with antigen pro- 
cessing. 
(7-11;  Luque,  I.,  and J.  Pena,  manuscript  submitted  for 
publication and personal communication). NK1  (group 1)- 
specifc cells  are unable  to  kill  target cells  expressing any 
HLA-C allele with Asn at position 77 (N77) and Lys at po- 
sition 80 (K80)  (Cw2, w4, w5, w6), whereas NK2 (group 
2)  cells  are  inhibited  by HLA-C  alleles  expressing Ser77 
and Asn80  (Cwl, w3, w7, wS). NK3-specific cells recog- 
nize  HLA-B  alleles  expressing  the  serologically  defned 
Bw4 determinant and are inhibited by allotypes containing 
Ile80 (11).  NK4-specific cells also recognize Bw4-express- 
ing cells,  but require Thr80  (Luque, I.,  and J.  Pena, per- 
sonal communication). 
The precise structural features required for HLA-C mol- 
ecules to be able to inhibit NK cells are not clear. Does the 
nature of the bound peptide affect the NKIR-HLA inter- 
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gested that the role of peptide was merely to promote the 
assembly and cell surface expression of MHC  class I mole- 
cules and that there was no peptide specificity in NK rec- 
ognition of MHC  class I (13). In contrast, Malnati et al (14) 
identified some  peptides  that  could  promote  assembly  of 
HLA-B27  and  confer  protection  from  B27-specific  NK 
cells, whereas  other B27-binding peptides could not  pro- 
tect.  Further,  since  in  HLA-C  alleles residues  77  and  80 
segregate together, which of these dimorphic residues is ac- 
tually important  for  NK  recognition?  Biassoni  et  al.  (15) 
used site-directed mutagenesis to define which of these po- 
sitions is important for inhibition by NK1  and NK2  cells. 
These  experiments suggested that  Lys80 in  Cw4  was  im- 
portant for NK1  inhibition whereas Ser77 in Cw3  defined 
the NK2 specificity; mutations at residues 77 (NKI) and 80 
(NK2)  had no effect. Given that the majority ofNK  speci- 
ficities correlate with the amino acid found at position 80, 
the result obtained was unexpected. 
To identify the precise structural characteristics required 
for inhibition of specific NK cells by HLA-C, we have mu- 
tated  residues  77  and  80  in  HLA-Cw4  and  Cw6  (NK1 
protection)  and  HLA-Cw3  and  Cw7  (NK2  protection). 
The  ability of these  mutants  to  inhibit lysis by NK1-  and 
NK2-specific  lines  and  clones  was  then  tested.  In  the 
present experiments, position 80 was defined as a key resi- 
due for control of recognition by both NK1  and NK2  el- 
lector cells. To assay whether specific peptide has any role 
in protecting cells from NK killing, we have tested whether 
HLA-Cw6  (NK1)  or HLA-Cw7  (NK2), when transfected 
into  RMA-S  cells, were  able to  inhibit NK  killing when 
stabilized by culture at reduced temperature in the absence 
of exogenously  added  peptide.  The  implications of these 
data for  recognition  of HLA class  I  molecules by specific 
NK cells are discussed. 
Materials and Methods 
The MHC class I-negative human B cell line 721.221  (16) was 
obtained from  the  American Type  Culture  Collection, Rock- 
ville, MD. RMA-S cells, which are TAP-deficient and therefore 
unable to load MHC class I molecules with peptide (13), were a 
kind gift of Kirsten Falk (Harvard University, Cambridge, MA). 
mAb HP3E4 (17) was a kind gift ofM. Lopez-Botet (Hospital de 
la Princesa, Madrid, Spain) and mAb GL183  (18) was purchased 
from Immunotech (Marseille, France). 
NK  cells were obtained from healthy adult donors MV  (A2, 
All; B18,  B44;  Cw5),  NQ  (A1,  A29; B35,  B51,  Cw4),  HTR 
(A1,  A2; B7,  B8;  Cw7),  DP  (A1,  A3, B7,  B8,  Cw7),  and AH 
(A1, A3, B8, B62, Cw9). PBMC were purified from heparinized 
venous  blood  by  centrifugation on  Ficoll-Hypaque (Phannacia, 
Piscataway,  NJ). NK lines were generated by culture of PBL with 
irradiated (3,000  rad) 721.221  cells  (3:1  PBMC:721.221,  7.5  ￿ 
105 PBMC/ml in RPMI 10% AB- hmnan serum). After 5-6 d of 
culture, pure preparations of CD3-,  CD56 +, CD16 + cells were 
obtained by depletion of contaminating T cells with mAbs against 
CD3  (T3D)  and CD4  (OKT4)  and rabbit complement (Cedar- 
lane  Laboratories, Hornby,  ON,  Canada).  NK  lines were  cul- 
tured in  RPMI,  10%  human  serum  supplemented with  l  mM 
glutamine, 1 mM nonessential amino acids,  1 mM sodium pym- 
vate, 2  X  10 -~ M  13-ME (all from GIBCO BRL,  Gaithersburg, 
MD), and 50 U/ml rhulL-2 (Boehringer Mannheim, Indianapo- 
lis, IN). NK clones were obtained by seeding NK lines at one or 
five  cells/well in  96-well U-bottomed plates in  complete  me- 
dium supplemented with  10% FCS,  10% leukocyte-conditioned 
medium (19),  and  1 b~g/ml  PHA (Wellcome, Greenville, NC). 
Irradiated feeder cells (2.5  X  104 allogeneic PBMC from two do- 
nors  and  5  X  103  RPMI  8866  B  cell line in  each  well) were 
added. Proliferating clones, as defined by growth at cell densities 
where growth of cells occurred in less than one third of the wells 
plated, were expanded in complete medium in 96-well plates. 
Mutagenesis.  cDNAs  encoding  HLA-Cw*0303,  HLA-Cw* 
04(i)1, HLA-Cw*0602,  and HLA-Cw*0702  were generated, via 
reverse transcriptase (RT)-PCR, using RNA isolated from the B 
cell lines Boleth (Cw3), CIR (Cw4), LBF (Cw6), andJY (Cw7), 
cloned  into  M13mp18,  and  sequenced  fully.  Mutagenesis  was 
carried out using the Sculptor in vitro mutagenesis kit (An~ersham 
Corp., Arlington Heights, IL) according to the manufacturer's in- 
structions. The sequences of the nmtagenic oligonucleotides used 
were KSON  (to replace Lys with Asp at position 80)  5'-GCC- 
GCGCAGGTTCCGCAGGTT-3',  N77S  5'-TTTCCGCAG- 
GCTCACTCGGTC-3',  N80K  5'-GCCGCGCAGTTTCCG- 
CAGGCT-3',  and  $77N  5'-GTTCCGCAGGTTCACTCG 
GGTC-3'.  Primers K80N  and N77S  were  used to  mutagenize 
Cw4 and Cw6, whereas primers N80K and $77N were used fbr 
mutagenesis of Cw3  and  Cw7.  The  wild-type Cw6  and  Cw7 
genes and the mutants were subcloned from M13 into pCDNA3 
that  encode  he0  (Invitrogen,  San  Diego,  CA)  for  transfection. 
The sequences of all mutants were verified by sequencing three 
times:  during  nmtagenesis in  M13,  after  introduction  into  the 
transfection vector, and after transfection into 721.221  cells. 
Tra~lsfectio,.  Plasmids were linearized with BgllI, and lO0 p,g 
of each plasmid was  used to  electroporate the  HLA-A, -B,  -C 
negative cell line 721.221  (16) with a gene pulser (Bio-Rad Lab- 
oratories, Richmond, CA) set at 23{) V and 250 I*Fd. After elec- 
troporation,  cells were  seeded in  24-well plates  (Costar Corp., 
Cambridge,  MA)  in  RPMI  medium  containing  10%  FCS, 
glutamine, nonessential amino acids, pyruvate, and mercaptoetha- 
nol  and  transfectants  selected  using  1.6  rag/nil  Geneticin 
(GIBCO BRL). Surface expression of HLA-C molecules was an- 
alyzed by  flow  cytometry using  the  pan-class I  mAb  W6/32. 
Clones exhibiting the highest levels of HLA-C expression were 
used as targets in cytolytic assays. 
Using  the  above  protocol,  RMA-S  cells  were  cotransfected 
with 100  b~g of a plasmid encoding the human 132-microglobulin 
([~2  m) gene and 1(I ~g of either the Cw6 or Cw7 plasmids.  Sur- 
face expression of HLA-C molecules was induced by culture at 
26~  in a humidified annosphere with 5% CO2  and was moni- 
tored by flow cytometry using the mAbs BB7.7 (hea W chain spe- 
cific) or BBM1  ([32m specific). 
Cytolytic Assays.  The cytolytic activity of NK lines and clones 
against the various HLA-C transfectants  and mutants was assessed 
in 5-h 3SS-release assays (4 h for the RMA-S targets) in which ef- 
lector cells were admixed with 5  X  103  [3SS]methionine-labeled 
targets at  different E/T  ratios in  U-bottomed microtiter plates. 
Assays were terminated by centrifugation at 1,000 rpm for 10 lnin 
at 4~  and 10{) Ftl of the supernatant was collected for liquid scin- 
tillation counting. Percent specific lysis was calculated as follows: 
% lysis =  [(cpm experimental well -  cpm spontaneous release)/ 
(cpm maximal release -  cpm spontaneous release)]  X  l{l{}. Spon- 
taneous release was determined by incubation of the labeled target 
cells with medium. Maximal release was detennined by solubiliz- 
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ing target cell in 0.1 M  NaOH. In all presented experiments, the 
spontaneous release was <25% of maximal release.  Each experi- 
ment was repeated three to six times. Error was <5%, of the mean 
of the  triplicates. In  experiments  where  NKIR-specific mAbs 
were used to block MHC-NKIR interaction, mAb was included 
in the medium to a final concentration of 2.5 Ixg/ml. 
Results 
Generation and Expression of HLA-Cw4/Cw6 and-Cw3/ 
Cw7 Molecules Mutated at Positions 77 and 80.  To  investi- 
gate the role of residues 77 and 80 in protection from NK1 
and NK2  effector cells, site-directed mutagenesis was  car- 
tied out in which the amino acids at either position 77  or 
80  in  the  NKl-protecting allele  (Cw4  or  Cw6)  was  re- 
placed with the residue found at the homologous position 
in the NK2 protecting allele (Cw3 or Cw7)  and vice versa. 
For example,  mutants  Cw6/K80N  and  Cw6/N77S  have 
the Cw6 backbone, but express Asn at position 80 and Ser 
at position 77,  respectively, whereas  mutants  Cw7/N80K 
and Cw7/S77N  have the Cw7  backbone, but express Lys 
at position 80  and Asn at position 77,  respectively. These 
mutant  constructs  and  the  wild-wpe  HLA-C  genes  were 
transfected  into  721.221  cells.  The  levels of HLA-C  ex- 
pression  of the  various  transfectants  were  monitored  by 
staining using the  mAb W6/32  (Fig.  1).  721.221  cells, as 
well as cells transfected with the  empty pCDNA3  vector, 
did not express detectable levels of MHC  class I molecules. 
The  existence  of specific  HLA-C  transcripts in  all of the 
721.221  transfected cells, including specific examination of 
the mutations introduced,  was  confirmed at least twice in 
each line using RT-PCR  (data not shown). 
Recognition of HLA-C by NK Lines and  Clones Generated 
from  NK1  and  NK2  Donors  Is  Controlled by  Residue  80. 
To test the role of residues 77 and 80 in NK recognition of 
HLA-C, NK lines and clones were generated from donors 
MV and NQ  (N77, K80 homozygous; NKl-specific cells) 
and from donors HTR,  DP  and AH  ($77,  N80  homozy- 
gous;  NK2-specific  cells)  as  described  in  Materials  and 
Methods.  M1  NK  lines  and  clones  (except  two  clones 
noted  below)  were  CD3  negative,  100%  CD56/CD16 
positive, and expressed NKIR molecules recognized by the 
mAbs HP3E4  and GL183  (data not shown). NK inhibition 
assays were performed with the MV NK1  (Fig. 2 A) or the 
DP NK2 line (Fig. 2  B). 721.221  cells were killed by both 
lines  to  the  same  extent.  721.221  cells  transfected  with 
Cw4  or Cw6  were protected from lysis by NKI-,  but not 
by  NK2-specific lines.  HLA-Cw3  and  Cw7  transfectants 
were  killed by  NK1  lines,  but  protected  from  killing by 
NK2 lines. Next, position 80 in the ocl domain was shown 
to  be  the  important  position  controlling  recognition  by 
Figure  1.  HLA-C  expression on  the  various transfectants. 721. 221 
cells were transfected  with various HLA-C genes as described in Materials 
and  Methods. Wild-type cells (721.221) and  the  various transfectants 
were stained with W6/32 antibody and than stained with anti-mouse IgG 
antibody bound to FITC (bold lines). Controls were the same cells stained 
only with anti-mouse  lgG bound to FITC (light lines). One out of four 
representative experiments is shown. 
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Figure  2.  Residue  80  of 
HLA-C allotypes determines in- 
hibition in NK lines. (A) Group 
1 specificity. (B) Group 2 speci- 
fici  W.  NK  lines prepared from 
donor  MV,  NKI  (.4) or  from 
donor l)P, NK2 (B) were reacted 
with various [,3~S]-methionine- 
labeled target cells for 5 h at wn- 
ious E/T ratios. Only the  E/T 
ratio of 10:l is shown. One out 
of six representatwe experinlents 
is shown. 
both  NK1  and  NK2  lines.  Target  ceils  expressing  K80 
(Cw4  wild-type, Cw6 wild-type, Cw4/N77S,  Cw6/N77S, 
Cw3/N80K,  and  Cw7/N80K)  were  protected  from  lysis 
by NK1  lines and killed by NK2 lines (Fig. 2 A), whereas 
target cells expressing N80 (Cw3 wild-type, Cw7 wild-type, 
Cw4/K80N,  Cw6/K80N,  Cw3/S77N,  and  Cw7/S77N) 
were protected from lysis by NK2-specific lines (Fig. 2 B). 
In both sets of experiments, lysis was reduced by >70% in 
916  NK Cell P,  ecognition of HLA-C Is Controlled by Residue 80 Table 1.  Residue  80 of HLA-C Allotypes is the Dominant Residue in Inhibition of NK1- and NK2-specific Clones 
Controls 
Transfectants 
NK  Cw3  Cw3  Cw4  Cw4  Cw6  Cw6  Cw7  Cw7 
clones  neo  721.21  Cw3  N80K  $77N  Cw4  K80N  N77S  Cw6  K80N  N77S  Cw7  N80K  $77N 
A  NK1 
MV1  27  28  29  9  27  0  30  0  0  29  0  28  0  29 
MV2  30  32  33  6  30  0  34  0  0  39  0  33  0  30 
MV3  50  54  56  6  45  0  49  0  0  44  0  43  0  40 
MV4  60  61  60  4  66  0  62  0  0  63  0  65  0  59 
MV5  31  39  33  0  34  0  29  0  0  32  0  31  0  33 
MV6  34  36  37  0  33  0  31  0  0  34  0  33  0  30 
Aver.  39  42  41  4  39  0  39  0  0  40  0  39  0  37 
B  NK2 
AH1  37  37  8  50  15  42  17  51  47  17  47  16  50  12 
AH2  23  24  0  20  0  19  0  19  24  0  24  0  25  0 
HTR31  31  32  0  27  0  30  0  33  32  0  23  6  20  0 
DP1  47  46  17  49  15  48  16  49  54  19  57  20  55  20 
DP2  73  74  19  79  33  78  30  81  86  32  90  22  79  14 
DP3  85  90  18  49  6  50  8  51  43  5  42  4  51  3 
DP4  43  44  0  40  3  41  0  43  39  3  46  2  43  1 
Aver.  48  50  9  45  10  44  10  47  46  11  47  10  46  7 
NK clones were prepared from NK1  donor (MV 1-6) (A) and from NK2 donors  (AH-1-2, HTR-31, DP-I-4 (/3) as described in Materials and 
Methods. Clones were reacted with the indicated [3sS]-methionine-labeled target cells for 5 h at various E/T ratios. Only data obtained at an E/T ratio 
1:1 are shown. One representative experiment out of three is shown. In each group, Aver. refers to the average killing or inhibition (in bold) of the 
panel of NK clones on the indicated target cell. 
relation to  the killing of 721.221  cells. Experiments were 
performed six times with three independently derived NK2 
lines from  donors  HTR,  DP,  and AH  and with  two  NK 
lines derived from donors MV and NQ. 
To confirm the above data at the clonal level, NK clones 
were  generated  from  donors  NQ,  MV,  AH,  DP,  and 
HTP,..  Table  1 summarizes experiments performed with 5 
NK1  clones and 7 NK2 clones. MV NK1  clones were de- 
rived from NKl-specific lines and stained with nLAb HP- 
3E4  (18),  but  not  GL183  (NK2  specific)  (19),  or  DX9 
(NK3 specific) (20). These clones showed the same pattern 
oflysis as the NKl-specific lines; all transfectants expressing 
K80 were protected from lysis (Table 1 A). The reciprocal 
picture  was  seen  in  killing  experiments  using  the  NK2 
clones. As in the case of the NK2-specific lines, target cells 
expressing N80  (Cw7  wild-type, Cw6/K80N,  and  Cw7/ 
$77N)  were protected from lysis (Table 1 /3). 
To  provide  direct  proof that  p58  (NKIP,)  molecules 
were involved in recognition of the mutated HLA-C alleles, 
the  NK1R.-specific mAbs HP3E4  and  GL183  were  tested 
for their ability to specifically reverse HLA-C-mediated in- 
hibition of NK  killing (Fig.  3).  Inclusion of mAb  GL183 
(which stains NK cell lines and clones inhibited by NK2 al- 
leles), but not mAb HP3E4  (which stains NK cell lines and 
clones inhibited by NK1  alleles) in the assay abrogated the 
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ability of HLA-C alleles expressing Asn80 to inhibit killing 
by  NK2  lines  and  clones.  Conversely,  addition  of mAb 
HP3E4, but not mAb GL183, to the assay blocked the abil- 
ity of HLA-C alleles expressing Lys80 to inhibit lysis medi- 
ated by NKl-specific effector cells. 
2  out  of 16  NK  2-specific clones tested were  inhibited 
by either Cw6/N77S-  or Cw6/K80N-expressing cells and 
1 out of 8 NK2 clones was inhibited by either Cw4/N77S 
or  Cw4/K80N.  These  clones  did not  express  any  of the 
NKIR defined by the available mAb to these receptors, and 
since NK clones may express multiple receptors (21), other 
as yet unidentified receptors may account for these observa- 
tions. Given the discrepancy with the result of Biassoni et al. 
(15), we considered that the use of NK cell lines as well as 
clones was important to establish that these properties were 
representative of the majority of the NK cell population. 
The present data on  the relative importance  of residues 
77  and  80  in  controlling recognition by NK2-specific el- 
lector cells are in conflict with the recent data of Biassoni 
et  al.  (15).  We  have  no  explanation  for  this  discrepancy 
other than to suggest that it may be a  result of the limited 
number of NK clones tested in those experiments. 
The Role of Peptide in Recognition of HLA-C by NK Lines 
and Clones.  Experiments  in  human  and  routine  model 
systems of NK recognition of MHC  class I molecules have A 
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Figure  3.  Reversal  of inhibi- 
tion of NK killing by pS8-specific 
antibodies, mAb GLl83, but not 
HP3E4, reverses HLA-C Asn80- 
mediated  inhibition  of  (A)  an 
NK2-specific  line  and  (B)  an 
NK2-specific clone, n~,b HP3E4, 
but not GL183,  reverses HLA-C 
Lys80-mediated inhibition of (C) 
an NKl-specific line and (D)  an 
NKl-specific clone, NK lines and 
clones prepared from donor MV 
(NK1) or from donor HTP. (NK2) 
were reacted at E/T ratios of 10:1 
for the lines,  or 1:1  fbr the clones 
with  various  pSS]methionine- 
labeled target cells for 5 h  in the 
presence or absence of the indi- 
cated antibodies (2.5  b~g/ml). 
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Figure 4.  Cell  surface expression of  HLA-C molecules on RMA-S cells after overnight culture at 26~  and 37~  P,  MA-S cells either untransfected or 
transfected with the indicated HLA-C genes, and hmnan ~2rn  were cultured overnight in a humidified atmosphere with 5% CO 2 at either 37 or 26~ 
Cells were stained with mAb BB7.7 and analysed by FACS  | 
produced discordant results with regard to the role of pep- 
tide in allorecognition by NK cells.  Correa and Raulet (12) 
reported  that  any  peptide  that  induced  stabilization,  and 
hence  cell surface  expression,  of the  MHC  molecule  was 
able to induce protection from NK cell-mediated lysis.  In 
contrast,  Malnati  et al.  (14)  have reported  that NK clones 
inhibited  by HLA-B2705 can  exhibit  a  degree  of peptide 
specificity in recognition of HLA. In the present study, this 
issue  was  addressed  by  transfecting  HLA-C  alleles  into 
R.MA-S  cells,  which  are  deficient  in  TAP  function  and 
thus  unable  to load peptides  onto  MHC  molecules.  Cul- 
ture  of R.MA-S  at  26~  results  in  surface  expression  of 
empty MHC  molecules that are apparently devoid of pep- 
tide  (13).  Various  R.MA-S transfectants were incubated  at 
either  37  or  26~  and  then  stained  with  mAb  BB7.7. 
RMA-S transfectants cultured overnight at 26~  expressed 
HLA-C  (Fig.  4).  Cell  surface  expression  of HLA-C  was 
maintained for at least 2 h after shift to culture at 37~  (data 
not shown). IkMA-S ceils transfected with either the wild- 
type HLA-C genes or the various mutant molecules were 
protected from NK lysis when cultured at 26~  in the ab- 
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sence of exogenously added peptide  (Fig.  5). P,  MA-S cells 
and the various transfectants were not protected from NK 
lysis  if cultured at 37~  This protection was specific since 
only P,.MA-S  cells  transfected  with  an  HLA-C  gene  ex- 
pressing Lys80 (Cw6, Cw6/N77S, Cw7/N80K) were pro- 
tected from lysis by a NK1 line (Fig. 5 A). In the reciprocal 
experiment,  only  HLA-C  molecules  with  Asn80  (Cw7, 
Cw7/S77N,  Cw6/K80N)  are able  to protect from a  NK2 
line (Fig.  5/3). Identical results were obtained in killing/in- 
hibition  assays  using  these  transfectants  and  the  panel  of 
NK1 and NK2 clones (data not shown). 
Discussion 
The  correlation  between  the  residue  found at  position 
80 and susceptibility  to NK cell lysis  was first observed in 
the relationship between the dimorphism at residues 77 and 
80 in HLA-C alleles  and  susceptibility  to lysis  (7).  Subse- 
quently, a similar correlation between susceptibility to lysis 
by  NK3  cells  and  the  presence  of I80,  T80,  or  N80  in 
HLA-B  alleles  was  also  observed  (11).  Residue  80  is  lo- A  MV  NK  line 
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Figure 5.  Killing  of RMA-S and transfectants  by (A) 
a  NKl-specific  line  and  (/3)  a  NK2-specific line. 
RMA-S and the indicated transfectants were cultured 
overnight at either 26 or 37~  and then used as targets 
in cytotoxici  W assays. None of the various HLA-trans- 
fected RMA-S cell lines incubated at 37~  were pro- 
tected from NK killing (data not shown). (A) Pattern 
of killing and inhibition obtained by assaying  the indi- 
cated targets (cultured at 26~  for susceptibility  to a 
NKl-specific line (MV). (/3) Results obtained when 
the effector cells were a NK2-specific  line (HTR). Per- 
cent specific lysis is shown at various E/T ratios. 
cated at the far side of the lip of the P9 pocket (F pocket) of 
class I MHC molecules, and its side chain points upwards (22); 
thus, its role in recognition by NK receptors can be readily 
understood. On the other hand, residue 77 is located deep 
in the P9 pocket and its side chain is not accessible to rec- 
ognition. The data of Biassoni et al.  (15; suggesting that a 
change in residue 80  did not affect  NK2  allorecognition, 
whereas  a  change  at  residue  77  abrogated  recognition), 
which we have been unable to reproduce were, therefore, 
extremely surprising. Residue 77  does,  however,  form an 
important residue in interaction with the P9 residue of the 
peptide. Its nature (S or N  in all HLA-C alleles)  could indi- 
rectly  affect  NK  recognition by  determining the  peptide 
that  can be bound, and possibly the  conformation of the 
molecule. The present data,  however,  show that  cell sur- 
face expression of HLA-C molecules, even in the absence 
of peptide,  is both necessary and sufficient to  inhibit HLA- 
C-specific NK lines and clones, and that residue 80 plays a 
critical role  in determining specificity of both  NKI-  and 
NK2-specific cells. This result strongly suggests that the site 
of the interaction between HLA molecules and the NKIR 
localizes to the top of the oil helix. 
The actual epitope recognized by NKIR on NK cells is, 
however, likely to be larger than a single anaino acid. It has 
been suggested that NK ceils interact with the "side" of the 
MHC molecule and recognize polymorphic residues in the 
920  NK Cell Recognition of HLA-C ls Controlled by Residue 80 ctl  helix  (23). We propose that the recognition site might 
be similar in position to the site occupied by Staphylococ- 
cal enterotoxin B and toxic shock syndrome toxin 1 (TSST-1) 
on top of and behind the od helix on class II MHC  mole- 
cules, but further towards the  COOH  terminus  of the od 
helix than  either  of these superantigens,  od-V65 in HLA- 
DR with which TSST-1  interacts is equivalent in position 
to ~x1-73T/A in HLA-Cw3/7,  respectively  (24).  Residue 
80 in HLA-C is thus two turns of the helix further toward 
the COOH  terminus than cil-V65 in class II MHC  mole- 
cules.  The precise  epitope  recognized by NK cells  in this 
region requires much further study,  and ultimately will be 
defined by detailed structural analysis. 
Moreover,  from  the  present  results,  peptide(s)  are  un- 
likely to be involved directly in recognition of the HLA-C 
molecule since the  empty molecules  expressed in RMA-S 
cells  at 26~  are inhibitory in a manner related only to ex- 
pression  of  the  appropriate  amino  acid  at  position  80. 
RMA-S cells do not express TAP, the peptide  transporter 
through which most peptides enter the endoplasmic reticu- 
lum  (ER)  for binding to class I MHC  proteins.  The entry 
of hydrophobic peptides formed through cleavage of signal 
sequences  within  the  ER  is  TAP  independent,  and  in  at 
least one case, HLA-A2 expressed in TAP-deficient human 
cells  (but  not HLA-B5  [25]),  some  HLA-A2 folds appro- 
priately with such hydrophobic peptides.  However, in that 
unusual  case, low level HLA-A2 expression  is seen at the 
cell  surface  at  37~  as  well  as  at  26~  (26,  27).  In  the 
present  case,  the  FACS  |  profile for HLA-C expression  in 
RMA-S at 37~  cells  can be superimposed on that of con- 
trol  cells,  i.e.,  no  HLA-C  appears  to  be  expressed.  It  is, 
therefore,  unlikely  that  these  class  I  MHC  proteins  bind 
TAP-independent peptides. 
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